Synlico

Executive Summary

Synlico is pioneering an AI-driven approach to drug discovery by integrating causal cell modeling, single-cell bioinformatics, and artificial intelligence. Founded in 2014 and based in San Francisco, the company aims to decode causality in cell biology, making cellular processes quantitatively explainable, predictable, and engineerable. This innovative platform has the potential to accelerate the development of potent therapies, particularly in the cell and gene therapy space. By shifting from correlation-based analysis to causal understanding, Synlico could improve drug target identification, reduce clinical failure rates, and enable more precise therapeutic interventions. The company's focus on causal AI in biology positions it at the forefront of a transformative trend in pharmaceutical R&D, though it remains early-stage with limited public information on specific programs.

Upcoming Catalysts (preview)

• Q3 2026Announcement of Lead Drug Candidate or Preclinical Data40% success
• Q1 2027Strategic Partnership or Collaboration with Major Pharma60% success
• Q4 2026Series A or B Financing Round70% success